Specialty Drug Reimbursement – Newsletter – July 2020 – Volume 20, Issue 7

INSIDE THIS ISSUE

Drug Reimbursement Code Price Updates

Drugs/Devices

      • New Clinical and Billing Information

    CMS News

      • New, Revised, and Deleted HCPCS® Effective July 1, 2020
      • Quarterly ASP (Average Sales Price) Pricing File Released
      • July 2020 NOC (Not Otherwise Classified) Pricing File
      • Hospital OPPS (Outpatient Prospective Payment System) Update

CODE UPDATES

Large Price Changes:

We identify and report on the codes with the most substantial pricing increases or decreases each month and detail the rationale for the change.

Of the 52 AWP Drug Code Price changes this month, 13 (25%) were price decreases. The table in the Drug Reimbursement Code Price Updates section includes all AWP drug Code Price changes for this month. Please note:  These numbers represent AWP Code Price changes only. See below for examples of codes with significant price changes this month.

LOOK UP PRICES NOW:

Price Decreases:

  • J0604 Cinacalcet, oral, 1 mg, (for ESRD on dialysis) (For billing prior to 1/1/18 use J8499), 26%
  • J1205 Injection, chlorothiazide sodium, per 500 mg, 21%
  • J1270 Injection, doxercalciferol, 1 mcg, 13%

Price Increases:

  • J1566  Injection, immune globulin, intravenous, lyophilized (e.g powder), not otherwise specified, 500 mg
    (Only Carimune NF, Panglobulin NF and Gammagard S/D should be billed using this code), 96%
  • S5551 Insulin, most rapid onset (Lispro or Aspart); 5 units (Code Price is based on median pricing methodology), 90%
  • J7321 Hyaluronan or derivative, hyalgan or supartz, for intra-articular injection, per dose
    (Hyalgan dose is 20 mg/2 mL and Supartz is 25 mg/2.5 mL) (Note: Total dose regimen = 3 – 5 injections), 52%

CMS News:

New, Revised, and Deleted HCPCS® Effective July 1, 2020

CMS (Centers for Medicare & Medicaid Services) have released a set of new, revised, and deleted HCPCS® codes effective July 1, 2020.  These codes will become billable on July 1st.  The following is a list of codes that will be available and/or revised.

New HCPCS® Codes:

J0223    Injection, givosiran, 0.5 mg

J0591    Injection, deoxycholic acid, 1 mg

J0691    Injection, lefamulin, 1 mg

J0742    Injection, imipenem 4 mg, cilastatin 4 mg and relebactam 2 mg

J0791    Injection, crizanlizumab-tmca, 5 mg

J0896    Injection, luspatercept-aamt, 0.25 mg

J1201    Injection, cetirizine hydrochloride, 0.5 mg

J1429    Injection, golodirsen, 10 mg

J1558    Injection, immune globulin (xembify), 100 mg

J3399    Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5×10^15 vector genomes

J7169    Injection, coagulation factor xa (recombinant), inactivated-zhzo (andexxa), 10 mg

J7204    Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu

J7333    Hyaluronan or derivative, visco-3, for intra-articular injection, per dose

J9177    Injection, enfortumab vedotin-ejfv, 0.25 mg

J9198    Injection, gemcitabine hydrochloride, (infugem), 100 mg

J9246    Injection, melphalan (evomela), 1 mg

J9358    Injection, fam-trastuzumab deruxtecan-nxki, 1 mg

Q4227   Amniocore, per square centimeter

Q4228   Bionextpatch, per square centimeter

Q4229   Cogenex amniotic membrane, per square centimeter

Q4230   Cogenex flowable amnion, per 0.5 cc

Q4231   Corplex p, per cc

Q4232   Corplex, per square centimeter

Q4233   Surfactor or nudyn, per 0.5 cc

Q4234   Xcellerate, per square centimeter

Q4235   Amniorepair or altiply, per square centimeter

Q4236   Carepatch, per square centimeter

Q4237   Cryo-cord, per square centimeter

Q4238   Derm-maxx, per square centimeter

Q4239   Amnio-maxx or amnio-maxx lite, per square centimeter

Q4240   Corecyte, for topical use only, per 0.5 cc

Q4241   Polycyte, for topical use only, per 0.5 cc

Q4242   Amniocyte plus, per 0.5 cc

Q4244   Procenta, per 200 mg

Q4245   Amniotext, per cc

Q4246   Coretext or protext, per cc

Q4247   Amniotext patch, per square centimeter

Q4248   Dermacyte amniotic membrane allograft, per square centimeter

Q5119   Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg

Q5120   Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg

Q5121   Injection, infliximab-axxq, biosimilar, (avsola), 10 mg

U0003   Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by  cms-2020-01-r

U0004   2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r

 

Revised HCPCS® Codes:

J7321  

Old Description: Hyaluronan or derivative, Hyalgan or Supartz or Visco-3, for intra-articular injection, per dose (Hyalgan dose is 20 mg/2 mL, Supartz and Visco-3 dose is 25 mg/2.5 mL) (Note: Total dose regimen = 3 – 5 injections)

New Description: Hyaluronan or derivative, hyalgan or supartz, for intra-articular injection, per dose

 

J9245

Old Description: Injection, melphalan hydrochloride, 50 mg

New Description: Injection, melphalan hydrochloride, not otherwise specified, 50 mg

 

Q4176

Old Description: NeoPatch, per square centimeter

New Description: Neopatch or therion, per square centimeter

 

Deleted HCPCS® Codes:

J9199  Injection, gemcitabine hydrochloride (infugem), 200 mg

There has been an update of the Hospital Outpatient Prospective Payment System (OPPS) through the addition and deletion of new HCPCS® Codes. These codes will be effective July 1st. The following is a list of codes which will be available, discontinued and/or revised for the July update:

New HCPCS® Codes:

C1748  Endoscope, single-use (i.e. disposable), upper gi, imaging/illumination device (insertable)

C1849  Skin substitute, synthetic, resorbable, per square centimeter

C9059  Injection, meloxicam, 1 mg

C9061  Injection, teprotumumab-trbw, 10 mg

C9063  Injection, eptinezumab-jjmr, 1 mg

C9122  Mometasone furoate sinus implant, 10 micrograms (sinuva)

C9803  Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus  2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source

Deleted HCPCS® Codes:

C9041   Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mg

C9053   Injection,  crizanlizumab-tmca, 1 mg

C9054   Injection, lefamulin (xenleta), 1 mg

C9056   Injection, givosiran, 0.5 mg

C9057   Injection, cetirizine hydrochloride, 1 mg

C9058   Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mg


Drug Reimbursement Code Price Updates:

This month, during our review of the 3079 Reimbursement HCPCS/CPT® Codes in our system, we identified 26 Drug Codes that required a recalculation of their AWP Code Price.  Log in to www.ReimbursementCodes.com to view the pricing updates for these codes.

90371

B5100 J1454 J7121
90670 C9041 J1566

J7314

90694 C9053 J1627

J7321

A4217

C9054 J1642

J7345

A4245

C9056 J1817

J7401

A4253

C9057 J1953

J7626

A4256

C9058 J2001

J9199

A4614

J2060 J9330

A6196

E0607

J2278 Q4180

A6220

E2100 J2315 Q4213

A6248

J0604

J2469 S5010

B4100

J1205 J7042 S5012

B4160

J1270 J7070 S5551

 


LOOK UP PRICES NOW:


Drugs/Devices: New/Updated Billing & Clinical Information

As new drugs come to market we review them for possible inclusion in our database. When a new drug is added to the database, we develop detailed clinical and billing information for the drug if appropriate.

Our review of existing drugs in our database with clinical and billing information already assigned identified six drugs that required updating.

Updated:

DAURISMO™ (glasdegib) tablets, for oral use – By Pfizer Labs

INLYTA® (axitinib) tablets, for oral administration By Pfizer

POMALYST® (pomalidomide) capsules, for oral use By Celgene

TALTZ® (ixekizumab) injection, for subcutaneous use By Eli Lilly and Company

RUBRACA® (rucaparib) tablets, for oral use By Clovis Oncology

STRENSIQ® (asfotase alfa) injection, for subcutaneous use – By Alexion Pharmaceuticals, Inc


RJ Health is a drug data, application & analytics provider to the pharmacy reimbursement market, who brings scalability to specialty drug innovation. We focus on specialty drug innovation (new approvals and additional indications), as well as normalizing reimbursement for drug classifications that have market forces at-play (generics / biosimilars, rebates, and CMS policy). The company provides industry-standard pricing, coding, dosing, weight, age, and diagnosis data & analyses to pharmacy, market access, claims, billing, finance, and network management clientele. RJ Health ensures transparency between manufacturer, payor, provider, pharmacies and their respective solution vendors (PBMs, Payment Integrity, Revenue Cycle, EHR, etc…) – all licensees of RJ Health data. 

Our tools and data:

Assist in understanding drug pricing and healthcare reimbursement for drug claims

Enable organizations to look up and crosswalk NDCs and HCPCS codes – J codes, C codes and other

Assist in calculating drug dosage accurately and ensure claims are reimbursed properly based on unit requirements

Ensure claim accuracy and crosswalk drug codes

Help organizations make the best decisions for drug formularies

Combine clinical diagnosis and procedural coding matched to the right drug and dosage, as well as the most cost-efficient specialty drug price


View last month’s newsletter.


© 2019 RJ Health Systems International, LLC.  All rights reserved. This newsletter and its contents are copyright protected.  No part of this newsletter may be reproduced in any manner by any means without written permission of RJ Health Systems International, LLC.

CPT copyright 2019 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.